The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
1-cyclopropyl-6-fluoro-4-oxo-7-(4-(2-oxo-2-(4-sulfamoylphenylamino)ethyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid ID: ALA5089465
PubChem CID: 166634333
Max Phase: Preclinical
Molecular Formula: C25H26FN5O6S
Molecular Weight: 543.58
Molecule Type: Unknown
Associated Items:
Names and Identifiers Canonical SMILES: NS(=O)(=O)c1ccc(NC(=O)CN2CCN(c3cc4c(cc3F)c(=O)c(C(=O)O)cn4C3CC3)CC2)cc1
Standard InChI: InChI=1S/C25H26FN5O6S/c26-20-11-18-21(31(16-3-4-16)13-19(24(18)33)25(34)35)12-22(20)30-9-7-29(8-10-30)14-23(32)28-15-1-5-17(6-2-15)38(27,36)37/h1-2,5-6,11-13,16H,3-4,7-10,14H2,(H,28,32)(H,34,35)(H2,27,36,37)
Standard InChI Key: SIEFLMWMMGPMBL-UHFFFAOYSA-N
Molfile:
RDKit 2D
38 42 0 0 0 0 0 0 0 0999 V2000
1.8655 -25.0316 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2.2782 -24.3259 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
1.4607 -24.3213 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
9.3509 -23.5375 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
9.3497 -24.3571 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0578 -24.7660 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.0560 -23.1287 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7646 -23.5339 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
10.7634 -24.3591 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4735 -24.7705 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
12.1894 -24.3612 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.1905 -23.5360 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4759 -23.1201 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
12.8993 -23.1291 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
13.6060 -23.5395 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
12.9013 -22.3119 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.4712 -25.5877 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.4759 -22.3029 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
11.0644 -26.2943 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
11.8816 -26.2966 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.6431 -23.1291 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
8.6417 -24.7651 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.9380 -24.3515 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.2321 -24.7561 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.2272 -25.5736 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
7.9345 -25.9849 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
8.6466 -25.5787 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.5177 -25.9790 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.8118 -25.5671 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1023 -25.9725 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.3964 -25.5607 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.8156 -24.7500 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.4039 -24.7432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6989 -24.3314 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9883 -24.7368 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.9872 -25.5582 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6928 -25.9663 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.2846 -23.5087 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 2 0
4 5 2 0
5 6 1 0
6 9 2 0
8 7 2 0
7 4 1 0
8 9 1 0
8 13 1 0
9 10 1 0
10 11 1 0
11 12 2 0
12 13 1 0
12 14 1 0
14 15 1 0
14 16 2 0
10 17 1 0
13 18 2 0
19 17 1 0
20 19 1 0
17 20 1 0
4 21 1 0
5 22 1 0
22 23 1 0
22 27 1 0
23 24 1 0
24 25 1 0
25 26 1 0
26 27 1 0
25 28 1 0
28 29 1 0
29 30 1 0
30 31 1 0
29 32 2 0
31 33 2 0
33 34 1 0
34 35 2 0
35 36 1 0
36 37 2 0
37 31 1 0
35 2 1 0
2 38 1 0
M END Associated Targets(non-human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 543.58Molecular Weight (Monoisotopic): 543.1588AlogP: 1.58#Rotatable Bonds: 7Polar Surface Area: 155.04Molecular Species: ACIDHBA: 8HBD: 3#RO5 Violations: 1HBA (Lipinski): 11HBD (Lipinski): 4#RO5 Violations (Lipinski): 2CX Acidic pKa: 5.62CX Basic pKa: 4.63CX LogP: 1.18CX LogD: -0.38Aromatic Rings: 3Heavy Atoms: 38QED Weighted: 0.41Np Likeness Score: -1.59
References 1. Ibrahim NM, Fahim SH, Hassan M, Farag AE, Georgey HH.. (2022) Design and synthesis of ciprofloxacin-sulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects., 228 [PMID:34871841 ] [10.1016/j.ejmech.2021.114021 ]